Back to Multiple Sclerosis
NCT05826028
NCT05826028
Who may be able to join
Who might be able to join this trial:
- You are an adult who has been diagnosed with secondary progressive multiple sclerosis (a form of MS that gradually gets worse over time), as confirmed by your doctor.
- Your level of physical disability falls within a specific range on a standard MS disability scale (meaning you have some disability but are still able to walk, at least with assistance).
- You are receiving or will receive the medication Mayzent (siponimod) through an approved patient access program or government subsidy scheme, and you meet the required criteria for that program.
Who may not be able to join:
- You cannot take the medication Mayzent due to a medical reason that makes it unsafe for you (confirm with trial site).
- You have been diagnosed with a different form of MS — specifically, either a first single episode (clinically isolated syndrome) or primary progressive MS (the type that worsens steadily from the very beginning).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Novartis Pharmaceuticals
Registry
clinicaltrials_gov
Start date
9 July 2020
Est. completion
20 April 2022
Where this trial is recruiting
🇦🇺 Australia
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Average time for siponimod onboarding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.